Mackenzie Financial Corp Has $40.98 Million Position in Boston Scientific Co. (NYSE:BSX)

Mackenzie Financial Corp boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 65.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 708,833 shares of the medical equipment provider's stock after buying an additional 279,513 shares during the quarter. Mackenzie Financial Corp's holdings in Boston Scientific were worth $40,978,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC lifted its holdings in shares of Boston Scientific by 112,306.1% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 18,661,660 shares of the medical equipment provider's stock valued at $863,475,000 after purchasing an additional 18,645,058 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $632,520,000. FMR LLC lifted its holdings in shares of Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider's stock valued at $6,648,595,000 after purchasing an additional 8,045,263 shares in the last quarter. Steadfast Capital Management LP purchased a new position in shares of Boston Scientific during the fourth quarter valued at approximately $138,969,000. Finally, American Century Companies Inc. lifted its stake in shares of Boston Scientific by 391.6% during the third quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider's stock valued at $172,752,000 after buying an additional 2,606,253 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares of the company's stock, valued at approximately $3,779,820.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares in the company, valued at approximately $3,779,820.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The disclosure for this sale can be found here. In the last three months, insiders sold 50,979 shares of company stock valued at $3,418,529. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 0.2 %

BSX traded down $0.16 during trading hours on Wednesday, reaching $67.96. 6,177,583 shares of the stock traded hands, compared to its average volume of 6,375,059. The firm's fifty day simple moving average is $67.17 and its two-hundred day simple moving average is $59.68. The company has a market cap of $99.70 billion, a price-to-earnings ratio of 63.51, a PEG ratio of 2.36 and a beta of 0.78. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $69.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period last year, the business earned $0.45 EPS. As a group, analysts forecast that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on BSX. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $70.00 to $72.00 and gave the company an "overweight" rating in a research note on Thursday, February 1st. Truist Financial upped their price objective on shares of Boston Scientific from $59.00 to $66.00 and gave the company a "buy" rating in a research note on Friday, December 22nd. Raymond James upped their price objective on shares of Boston Scientific from $67.00 to $73.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 1st. Mizuho raised shares of Boston Scientific from a "neutral" rating to a "buy" rating and upped their price objective for the company from $65.00 to $80.00 in a research note on Thursday, February 1st. Finally, Argus increased their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a "buy" rating in a research note on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $68.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.